Methylprednisolone hemisuccinate
- Generic Name
- Methylprednisolone hemisuccinate
- Brand Names
- Solu-medrol
- Drug Type
- Small Molecule
- Chemical Formula
- C26H34O8
- CAS Number
- 2921-57-5
- Unique Ingredient Identifier
- 5GMR90S4KN
- Background
A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.
- Associated Conditions
- Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis
- Associated Therapies
- Palliative Treatment
Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase 2
- Conditions
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2014-01-10
- Target Recruit Count
- 180
- Registration Number
- NCT01005758
Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
- First Posted Date
- 2009-11-01
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 11
- Registration Number
- NCT01005914
- Locations
- πΊπΈ
OHSU Knight Cancer Institute, Portland, Oregon, United States
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-10-23
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT01000610
- Locations
- πΉπ³
Hopital Farhat Hached; Service Rhumatologie, Sousse, Tunisia
πΉπ³Hopital La Rabta; Service Rhumatologie, Tunis, Tunisia
πΉπ³Hopital Charles Nicole; Service Rhumatologie, Tunis, Tunisia
Preoperative Methylprednisolone in Endovascular Aortic Repair
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-10-05
- Last Posted Date
- 2014-11-14
- Lead Sponsor
- Louise de la Motte
- Target Recruit Count
- 150
- Registration Number
- NCT00989729
- Locations
- π©π°
Department of Vascular Surgery, Rigshospitalet 3111, Copenhagen, Denmark
Effects of Methylprednisolone After Total Knee Arthroplasty
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2012-09-26
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT00968578
- Locations
- π©π°
Hvidovre University Hospital, Copenhagen, Hvidovre, Denmark
Effects of Methylprednisolone After Total Hip Arthroplasty
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2011-09-29
- Lead Sponsor
- Hvidovre University Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT00968903
- Locations
- π©π°
Hvidovre University Hospital, Copenhagen, Hvidovre, Denmark
Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2009-07-28
- Last Posted Date
- 2016-03-22
- Lead Sponsor
- Neurologique Foundation, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00947895
- Locations
- πΊπΈ
Neurologique Foundation, Inc., Ponte Vedra, Florida, United States
Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-06-29
- Last Posted Date
- 2017-08-21
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 164
- Registration Number
- NCT00929695
- Locations
- πΊπΈ
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma
Phase 3
Terminated
- Conditions
- Interventions
- Biological: bleomycin sulfateDrug: ABVD regimenDrug: cisplatinDrug: carmustineDrug: cytarabineDrug: dacarbazineDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: etoposideDrug: gemcitabine hydrochlorideDrug: methylprednisoloneDrug: vincristine sulfateDrug: ifosfamideDrug: vindesineDrug: melphalanDrug: mitoguazoneDrug: vinorelbine tartrateProcedure: allogeneic hematopoietic stem cell transplantationProcedure: autologous hematopoietic stem cell transplantation
- First Posted Date
- 2009-06-15
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- French Innovative Leukemia Organisation
- Target Recruit Count
- 442
- Registration Number
- NCT00920153
- Locations
- π«π·
FILO French Innovative Leukemia Organization, Tours Cedex, France
Greater Occipital Nerve Block for Migraine Prophylaxis
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2014-03-20
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 70
- Registration Number
- NCT00915473
- Locations
- πΊπΈ
Mayo Clinic, Phoenix, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2024. All Rights Reserved by MedPath